Staff Writer
Articles
FDA Approves Cooling Cap Across Solid Tumors
July 03, 2017
Article
The indication for the DigniCap Cooling System has been expanded by the FDA to include alopecia reduction across all solid tumors.
Higher VTE Incidence With Cisplatin Chemotherapy
May 30, 2017
Article
Patients treated with cisplatin-based chemotherapy had a higher risk of venous thromboembolism.
Phase III Trial to Examine Veliparib in BRCA Positive Breast Cancer
April 19, 2017
Article
An ongoing trial is evaluating the addition of PARP inhibitor velaparib to a chemotherapy combination, for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.
Novel Immunotherapy Under Study in Pancreatic Cancer
March 27, 2017
Article
An ongoing trial is evaluating the combination therapy of interleukin-10 agonist AM0010 and FOLFOX chemotherapy, for patients with metastatic pancreatic cancer.
Survival Benefit Confirmed With Maintenance Olaparib in BRCA+ Ovarian Cancer
March 23, 2017
Article
For patients with BRCA+ ovarian cancer, olaparib in the maintenance setting has shown impressive progression free survival benefits.
Survey Examines Why US Uptake of HPV Vaccine Remains Relatively Low
March 15, 2017
Article
According to a recent survey, the main causes for a lack of HPV vaccine uptake are a lack of knowledge and a failure by healthcare providers to recommend it.
Ibrutinib Granted FDA Approval for Marginal Zone Lymphoma
January 19, 2017
Article
The FDA has granted accelerated approval of ibrutinib for treatment of marginal zone lymphona (MZL).
Survey Spotlights Symptom Burden With Myeloproliferative Neoplasms
December 20, 2016
Article
A recent survey indicates that many patients with MPNs experience a high symptom burden that affects their emotional wellbeing, quality of life, and functionality.
Survival Advantage with Olaparib for Patients with Ovarian Cancer in Phase III Study
November 01, 2016
Article
In a recent phase III study, the PARP-inhibitor olaparib was shown to improve progression-free survival for patients with BRCA-positive ovarian cancer.
CDK 4/6 Inhibitors: A Growing Role in Breast Cancer
October 25, 2016
Article
An update on CDK4 and CDK6 inhibitors in treatment for patients with metastatic breast cancer.